Biocon Biologics, Malaysian Cancer Body Tie Up To Expand Access To Biosimilars

Biocon Ltd. on Tuesday said its subsidiary Biocon Biologics Ltd. has signed a memorandum of understanding with the National Cancer Society of Malaysia to launch a patient assistance programme aimed at improving access to biosimilars for underserved cancer patients in the country.

Under the partnership, Biocon Biologics will supply biosimilars from its oncology portfolio, while the National Cancer Society of Malaysia will oversee patient enrolment and ensure medicine distribution as part of its healthcare services, the company said in an exchange filing.

The initiative will begin with the provision of Trastuzumab, a key treatment for HER2-positive breast cancer, to patients who are experiencing treatment delays due to budget limitations.

The agreement was signed on the sidelines of the National Cancer Congress Malaysia 2025 held earlier this month in Kuala Lumpur.